Results 11 to 20 of about 111,516,708 (187)
Diagnostics, 2023 Tumor marker determinations are valuable tools for the guidance of breast cancer patients during the course of disease. They are assessed on diverse analytical platforms that may be associated with differences according to the methods applied and the ...
Lars Schröder +9 more
doaj +1 more source
Tumor marker CA 15-3 in breast cancer patients [PDF]
Acta Medica Academica, 2015 Objective. The aim of this study was to determine whether there is a correlation between the serum concentration of the tumor marker CA 15-3 and breast cancer, which has not been proven by the existence of regional and distant metastases, and breast ...
Hanifa Fejzić +3 more
doaj +1 more source
Clinical usefulness of cancer markers in primary breast cancer [PDF]
, 2011 The aim of this study was to investigate the diagnostic power of CA 549, MSA and CA 15-3 in identifying breast cancer. The study included 232 patients of which 56 were healthy, 43 had benign breast cancer and 191 with other growths.
Verring, A. +3 more
core +1 more source
Cancer Treatment and Research Communications, 2021 Background: We aimed to evaluate the association of serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3) levels with clinicopathological parameters in patients with breast cancer (BC) and their efficiency for the prediction of ...
Meliha Melin Uygur, Mahmut Gümüş
doaj +1 more source
Case Reports in Oncology, 2021 A 73-year-old woman with no history of disease was referred to our hospital with fatigue and joint pain. Screening blood test showed that her cancer antigen 15-3 (CA 15-3) serum level was elevated to 36.6 U/mL, and a contrast-enhanced computed tomography
Koichiro Takayama +4 more
doaj +1 more source
Comparison of Prolactin, CA 15–3 and TPA in Breast Carcinomas
The International Journal of Biological Markers, 1989 Circulating prolactin, CA 15–3 and TPA were assayed pre-therapeutically and sequentially thereafter from 68 breast cancer patients attending the Gujarat Cancer and Research Institute, Ahmedabad — a regional cancer institute in Western India.
J.M. Bhatavdekar +7 more
doaj +1 more source
Breast, 2020 Background: Serum tumour markers, cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) are not routinely recommended for detecting breast cancer recurrence and monitoring treatment. In this study, we aim to evaluate the diagnostic accuracy of
J.X. Hing +6 more
doaj +1 more source
Clinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection
Frontiers in Oncology, 2023 BackgroundWithout organized screening programs up to 60-70% of breast cancers are diagnosed at advanced stages that have significantly lower five-year survival rate and poorer outcomes, which is a serious global public health problem.
Marina Sekacheva +4 more
doaj +1 more source
Tumor Markers in Dogs with Mammary Gland Tumors
Acta Veterinaria, 2023 The aim of this study was to determine and compare values of carcinoembryonic antigen (CEA) and cancer antigen (CA 15-3) in 50 bitches with mammary tumors and 150 clinically healthy dogs.
Valencakova Alexandra +4 more
doaj +1 more source
Tissue ELISA and Serum Amperometric Magnetoimmunosensor of ECD-HER2 In Stratifying Subtyping of Egyptian Woman Breast Cancers [PDF]
Zagazig University Medical JournalBackground: Detection of HER2 extracellular domain (ECD) amperometric magnetoimmunosensor (AM) investigated on raw cell lysates, intact breast cancer cells, and commercial and healthy sera except on patients' samples.
Sameh Nakhla +12 more
doaj +1 more source